Short-term Efficacy And Safety Of C-TACE+D-TACE In The Treatment Of Advanced Primary Hepatocellular Carcinoma

Objective: To investigate the short-term efficacy and safety of C-TACE combined with D-TACE in the treatment of advanced primary liver cancer.Methods: According to the inclusion criteria,a total of 42 patients with advanced primary hepatocellular carcinoma were selected as the research subjects.Among them,20 patients were treated with C-TACE+D-TACE and were assigned to the experimental group.Another 22 patients were treated with C-TACE as control group.After operation,the short-term efficacy of the two groups was evaluated by the m RECIST standard and the changes of serum alpha-fetoprotein(AFP).In addition,the blood routine,liver function,laboratory indicators of renal function,adverse reactions and complications were compared between the two groups before and after interventional therapy.Results: Before operation,there was no significant difference in basic clinical features,serum AFP level and related laboratory indicators between the two groups(P > 0.05).There was no significant difference in AFP level before and after operation(P > 0.05).In the first month after operation,the disease control rate(DCR)and objective remission rate(ORR)were 85.00% and 15.00% in C-TACE + D-TACE group,72.73% and 22.73% in C-TACE group,respectively.At the second month after operation,the disease control rate(DCR)and objective remission rate(ORR)were 60.00% and 10.00% in C-TACE + D-TACE group,54.55% and 27.27% in C-TACE group,respectively.There was no significant difference in disease control rate and objective effective rate between the two groups(P > 0.05).ALB,HGB,PLT decreased and TBIL,ALT and AST increased in the two groups within one week after operation,but there was no significant difference in the degree of change between the two groups(P > 0.05);WBC increased in the experimental group(P < 0.05),while WBC in the control group had no significant difference;UREA,CREA and GFR in the two groups had no significant difference.Conclusion: In the near future,there is no significant difference in objective remission rate and disease control rate between C-TACE + D-TACE and C-TACE(P > 0.05).In addition,the adverse reactions of C-TACE + D-TACE group are higher.